PMS2 and cancer: Our validation of this formula demonstrates that it is fully concordant with PMS2 variant classification based on clinical or phenotypic (genetic screen‐derived) criteria, with a bimodal distribution of the OddsPath between cancer predisposing and benign variants, despite the conservative approach for calibration of PMS2 variants as compared to calibration of the CIMRA assay for variants in the other three MMR genes.